Market Overview

Weekly Analyst Highlights: Oil, Tesla On Readers' Minds

Weekly Analyst Highlights: Oil, Tesla On Readers' Minds
Related TSLA
Liability In Autonomous Car Crashes: Here's What Gene Munster, Warren Buffett And GM Say
Should Investors Take Elon Musk's Tweets Seriously?
Volvo Goes After Tesla On Key Battlefronts (Not Only With The Uber Order) (Seeking Alpha)
Related RIG
Jim Cramer Weighs In On Universal Display, Kinder Morgan And More
Oil & Gas Stock Roundup: TOTAL, Encana, And More
Ensco: Favorable Risk/Reward Opportunity In The Beaten Down Sector With 8.4% Fixed Yield And 50% Upside (Seeking Alpha)

Below are the most-read analyst stories from the past week on Benzinga.

1. Analysts at Bank of America are not buying into the Tesla Motors Inc (NASDAQ: TSLA) hype. Analyst John Lovallo cut the price target from $70 to $65, expecting the stock to plummet more than 70 percent.

The analyst said that the company is facing a 'no demand' scenario and is "pulling back on production" in order to "create the appearance of rising demand."

2. Crude oil declined in early Monday trading, putting oil stocks under pressure. Transocean Ltd. (NYSE: RIG) was down by 3 percent.

Analysts at Morgan Stanley do not expect the pressure to abate, as US crude stocks are "elevated and set to build through May," which may lead to increased volatility, but offers "limited" upside.

Related Link: 9 Movers (Including EYES) To Keep An Eye On

3. Barclays analysts forecasted a decline in oil production growth for the companies in its coverage universe, from 14 percent growth in 2014 to only 8 percent in 2015. While this news may be positive for oil investors, the analysts believe many E&P names, such as United States Oil ETF (NYSE: USO), remain overpriced at current levels.

"We believe the stocks discount a price recovery to $80-85/bbl oil, a level that is 30-35 percent higher than the current 2016 strip," they explained in the report.

4. Oncothyreon Inc (NASDAQ: ONTY) climbed on Wednesday afternoon on rumors of a possible move on Pharmacyclics, Inc. (NASDAQ: PCYC). In a report, Bernstein analysts said that the valuation looks "a bit too pricey (…) In other words: you have a $1B asset generating $30B in biotech company valuation."

Deutsche Bank also commented that the valuation is too high.

5. GoPro Inc (NASDAQ: GPRO) dipped 4 percent on Monday, after an analyst said the company will go nowhere unless it can beat giant competitors in the development of video-editing software. Morgan Stanley analyst James Faucette initiated coverage on GoPro with an Equal-Weight rating and a $57 price target.

"If GoPro is the one who successfully brings that to market, then you have a lot of upside," Faucette commented.

Image credit: Vlad Lazarenko, Wikimedia

Latest Ratings for TSLA

Oct 2017Evercore ISI GroupDowngradesOutperformIn-Line
Oct 2017Morgan StanleyMaintainsEqual-WeightEqual-Weight
Oct 2017Standpoint ResearchDowngradesHoldSell

View More Analyst Ratings for TSLA
View the Latest Analyst Ratings

Posted-In: Bank of America Barclays Bernstein Deutsche BankAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga


Related Articles (ONTY + GPRO)

View Comments and Join the Discussion!

Partner Center